MedLink and Huxi Jia Join Forces to Bridge the Last Mile in Respiratory Chronic Disease Management

Recently, Medlinker, a leading chronic disease management platform in China, has entered into a strategic partnership with Huxijia to jointly conduct frontier explorations and academic research in the field of chronic disease management for respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). This collaboration aims to integrate Medlinker’s professional platform service capabilities in chronic disease management with Huxijia’s comprehensive whole-course management solutions for respiratory chronic diseases, which are based on IoT medical devices and cloud-based business systems. By covering all aspects of chronic disease management, the partnership seeks to streamline the entire process of chronic disease management for respiratory disorders.

In China, the number of patients with respiratory diseases is substantial, exceeding 150 million, including 60 million asthma patients and 100 million patients with chronic obstructive pulmonary disease (COPD). In recent years, due to air quality issues, the number of patients with chronic respiratory diseases continues to grow. For instance, the incidence rate of childhood asthma in China has increased by 64.84% over the past decade, while the asthma patient population grows at an annual rate of 4%, accompanied by extremely high medical expenditures. Data shows that for COPD patients, the total treatment cost per case accounts for 40% of the average household’s total income. Furthermore, COPD patients experience approximately 0.5 to 3.5 acute exacerbations per year, with the average hospitalization cost reaching RMB 11,598 per episode.

Furthermore, bronchial asthma (hereinafter referred to as “asthma”), as one of the respiratory diseases, is also a common chronic disease worldwide. Despite significant advances in current medical technologies, asthma remains a globally recognized medical challenge.

Therefore, Medlinker believes that the treatment goals for chronic respiratory diseases are to achieve indicator control of relevant symptoms, reduce exacerbations, and mitigate risks such as irreversible lung function impairment. To achieve the goal of disease control, it is crucial to enhance patients' self-management capabilities. Patients need to adhere to long-term treatment under the scientific and professional guidance of physicians to effectively control their condition and maintain a normal quality of daily life. In 2016, chronic respiratory diseases were officially included as a key priority in the National Key R&D Program’s Special Project on the Prevention and Control of Major Chronic Non-communicable Diseases during the 13th Five-Year Plan period.

Regarding the collaboration between Medlinker and Breathing Home, a representative from Medlinker stated, “Medlinker has been deeply engaged in the field of chronic disease management for many years. We highly recognize and value Breathing Home’s extensive experience in medical devices, health management, the Internet of Things (IoT), and mobile internet. By joining forces with Breathing Home, Medlinker can effectively integrate its platform capabilities, physician service capabilities, and artificial intelligence big data capabilities—accumulated over years in chronic disease management—with Breathing Home’s software and hardware infrastructure. This deep collaboration aims to enhance efficiency and effectiveness in the management of respiratory chronic diseases, achieving the goal of ‘liberating physicians and serving patients.’ Furthermore, it will establish a comprehensive chronic disease management pathway spanning ‘monitoring–diagnosis and treatment–management,’ delivering more considerate and convenient digital medical services to a broader population of respiratory patients.”

A representative from Huxijia stated, “This strategic partnership with Medlinker aims to complement the respective business strengths of both parties. Through synergy across front-end, mid-end, and back-end operations, we will establish a more comprehensive medical-grade product, platform, and service system. Our goal is to build an advanced and scientifically grounded ‘Chronic Respiratory Disease Diagnosis and Treatment Management System,’ creating a closed-loop model for the integrated management of screening, referral, treatment, and rehabilitation of chronic respiratory diseases. In the future, Huxijia and Medlinker will continue to explore chronic disease management in pulmonology, providing patients with more scientific treatment plans.”

Medlinker, established in 2014, is a leading chronic disease management platform in China. It is committed to providing long-term, standardized specialized chronic disease management services to a broad population of patients with chronic conditions, leveraging technology to help them achieve a high quality of life. Currently, the Medlinker platform brings together more than 800,000 real-name verified physicians and over 50,000 contracted doctors across China. Its services span multiple chronic disease areas, including liver disease, diabetes, HIV, oncology, nephrology, cardiovascular and cerebrovascular diseases, attention-deficit/hyperactivity disorder (ADHD) in children, mental health and psychological disorders, and respiratory conditions such as asthma. The platform provides patients with a range of effective, affordable, and accessible out-of-hospital chronic disease management services, including treatment recommendations, evaluation of therapeutic outcomes, electronic prescriptions, medication guidance, psychological counseling, and lifestyle interventions, thereby ensuring effective control of their conditions.

A professional service provider specializing in digital therapeutic technologies for telemedicine, founded by a team of seasoned experts with many years of experience in medical devices, health management, the Internet of Things (IoT), and mobile internet. After six years of innovative research and development, the company has established a comprehensive system of medical-grade products, platforms, and services, including IoT-based medical product lines such as the “Pulmonary Function Test Series,” “Respiratory Rehabilitation Series,” and “Smart Medication Management Series.” It pioneered China’s first cloud-based doctor-patient interaction platform, “Breathing Home,” and built a digital healthcare big data system.